Study Evaluating MST-997 in Advanced Malignant Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical research study is to evaluate the safety,
tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in
Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid
tumors.